Cell Metabolism, volume 31, issue 6, pages 1068-1077000
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
Lin Zhu
1
,
Zhi-Gang She
1
,
Cheng Xu
1
,
Juan‐Juan Qin
1
,
Xiao-Jing Zhang
1
,
Jingjing Cai
2
,
Lei Fang
1
,
Haitao Wang
3
,
Jing Xie
4
,
Wen-Xin Wang
1
,
Hao-Miao Li
1
,
Peng Zhang
5
,
Xiaohui Song
1
,
Xi Chen
3
,
Mei Xiang
6
,
Chaozheng Zhang
1
,
Liangjie Bai
1
,
Da Xiang
1
,
Ming Chen
1
,
Yanqiong Liu
1
,
Youqin Yan
7
,
Mingyu Liu
8
,
Weiming Mao
9
,
Jinjing Zou
10
,
Liming Liu
11
,
Guohua Chen
12
,
Pengcheng Luo
13
,
Bing Xiao
14
,
CHANGJIANG ZHANG
15
,
Zixiong Zhang
16
,
Zhigang Lu
17
,
Junhai Wang
18
,
Haofeng Lu
19
,
Xigang Xia
20
,
Daihong Wang
21
,
Xiaofeng Liao
22
,
彭钢 Gang Peng
23
,
Ping Ye
6
,
Jun Yang
24
,
Yufeng Yuan
3
,
Xiao-Dong Huang
25
,
Binbin Zhang
26
,
Hongliang Li
15
7
Wuhan Seventh Hospital, Wuhan 430072, China
|
8
The Ninth Hospital of Wuhan City, Wuhan 430072, China
|
9
Department of General Surgery, Huanggang Central Hospital, Huanggang 438000, China
|
11
Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, China
|
12
Department of Neurology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430072, China
|
14
Department of Stomatology, Xiantao First People’s Hospital, Xiantao 433000, China
|
16
The Central Hospital Of Enshi Tujia And Miao Autonomous Prefecture, Enshi 445000, China
|
19
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Changjiang University, Jingzhou 434000, China
|
20
Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou 434000, China
|
21
Department of Hepatobiliary and Pancreatic Surgery, Xianning Central Hospital, Xianning 437000, China
|
23
Department of Hepatobiliary and Pancreatic Surgery, Suizhou Central Hospital Affiliated to Hubei Medical College, Suizhou 441300, China
|
Publication type: Journal Article
Publication date: 2020-06-01
Journal:
Cell Metabolism
scimago Q1
wos Q1
SJR: 11.406
CiteScore: 48.6
Impact factor: 27.7
ISSN: 15504131, 19327420
Molecular Biology
Cell Biology
Physiology
Abstract
Summary
Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.